Research Progress on the Structural Classification and Functional Applications of Lasso Peptides
Lasso peptides, a class of ribosomally synthesized and post-translationally modified peptides (RiPPs), are named for their characteristic interlocked lasso topology.
September 9, 2025
by Xiaonisha
Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections
Antabio’s MEM-ANT3310 is a next generation broad-spectrum antibacterial combination that has been designed to address the growing problem of antimicrobial resistance in severe hospital infections.
October 14, 2024
by PharmaSources
FDA finalises guidance, ‘Limited Population Pathway for Antibacterial and Antifungal Drugs’
This guidance is intended to assist sponsors in developing labelling, including prescribing information, patient labelling, and carton/container labelling for drugs approved under the LPAD pathway.
August 7, 2020
by expresspharma
Could Antibacterial Triclosan Weaken Women's Bones?
Could Antibacterial Triclosan Weaken Women's Bones?
June 26, 2019
by drugs
FDA expands label for Allergan’s antibacterial Avycaz By Allie Nawrat
FDA expands label for Allergan's Avycaz to include children with cIAI's and cUTI's. Credit: Shutterstock.
March 20, 2019
by pharmaceutical-technology
Omadacycline similar to commonly-used antibiotics for treating pneumonia, skin infections
Findings of two phase III, double-blind, randomised clinical trials comparing omadacycline with standard antibiotics have been published in the New England Journal of Medicine
February 13, 2019
by europeanpharmaceuticalreview
Hidden Dangers in Dust
An antibacterial called triclosan is common in dust and could result in dust-dwelling bacteria becoming antibiotic-resistant, researchers report......
December 12, 2018
by drugs
Antibacterial drugs market to be worth US$51 billion by 2025
Global antibacterial drugs market to gain impetus from strategic collaborations among leading enterprises, says research.
December 28, 2017
by pharmaasia
Levofloxacin still Got it?
The market performance of levofloxacin was eye-catching after marketing owing to its strong antibacterial action, good efficacy, and small side effects, etc., with the sales continuing to grow and the product rapidly becoming a star product on Chinese and
December 8, 2017
by en-cphi.cn
The Medicines Co. nets $400M nod for UTI antibacterial treatment
Vabomere's peak sales will hit $400 million in 2028, one analyst predicts.
August 31, 2017
by fiercepharma